Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

Massimo Colombo

Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

Massimo Colombo

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	Journal of Viral Hepatitis
Volume	19 Suppl 1
Publication status	Published - Jan 2012

ASJC Scopus subject areas

Hepatology
Infectious Diseases
Virology

Cite this

@article{c3845a46c5144d3b8ff53791b491bb70,

title = "Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.",

author = "Massimo Colombo",

year = "2012",

month = jan,

language = "English",

volume = "19 Suppl 1",

pages = "1--2",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

AU - Colombo, Massimo

PY - 2012/1

Y1 - 2012/1

UR - http://www.scopus.com/inward/record.url?scp=84860556947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860556947&partnerID=8YFLogxK

M3 - Article

C2 - 22233406

AN - SCOPUS:84860556947

SN - 1352-0504

VL - 19 Suppl 1

SP - 1

EP - 2

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

ER -

Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

ASJC Scopus subject areas

Other files and links

Cite this